drugset / Trial / NCT02947711
Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P glycoprotein \[Pgp\] inhibitor) on the pharmacokinetics (PK) of a single oral dose of E2027 in healthy participants.
Timeline
- Start
- 2016-10
- Primary completion
- 2016-11
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irsenontrine | Small molecule | 100 mg | Oral |
| Background | Diltiazem | Small molecule | 300 mg | — |
Indications
No indication recorded.